E273K
Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorialGlutamate → Lysine at position 273 in N-terminal cytoplasmic domain. ClinVar Conflicting with broad spectrum — Cataract 41, DFNA6. AlphaMissense 0.15 (below threshold) — AM under-call. DynaMut2 ΔΔG +0.25. pLDDT 29 — Category 5 IDR!
Interactive 3D Structure
Computational Predictions
Clinical Evidence
Observed in the general population.
Structural Context
Position 273 at pLDDT 29 — deep in the IDR region. Sparse neighbor analysis (only sequence neighbors LEU274, ASP272, ALA275 within 5 Å) confirms IDR character. DynaMut2 prediction not trustworthy.
AM 0.15 below threshold. Multi-phenotype clinical evidence (Cataract 41, DFNA6) confirms — but the IDR mechanism is invisible to AM.
Druggability Assessment
The Atlas routes Category 5 variants to wet-lab characterization. Multi-phenotype confirms clinical pathogenicity — mechanism likely IDR-mediated.
Why this matters
Feed this card to Wolfram Intelligence
Download the E273K PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.